Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed

Conditions studied: Transplant Rejection, Allograft Rejection, Complications

In brief

This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis, called Prospera.

Key facts

Study ID

NCT03984747

Run by

Natera, Inc.

People needed

110

Starts

2018-09-14

Expected to finish

2024-08-23

Last updated by the study team

2025-03-18

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must be 2 years old or older at the time of enrollment
• Subject or Legally Authorized Representative is willing and able to sign the informed consent form (and assent form, if applicable), prior to participation in any study-related procedures.
• Subject has received at least one organ transplant prior to enrollment.

You may not qualify if…

• Pediatric subjects under 2 years old
• Subject received donor organ from an identical twin

Where it is running

• Natera Inc. — San Carlos, California, United States
• Balboa United California Institute of Renal Research — San Diego, California, United States
• Children's Hospital at Montefiore — The Bronx, New York, United States
• The Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.